Scleroderma

Tocilizumab Preserves Lung Function in Early Systemic Sclerosis

Tocilizumab prevents progression of interstitial lung disease in patients with early systemic sclerosis (SSc).

Meta-Analysis Assesses Safety and Efficacy of Rituximab in Patients With Systemic Sclerosis

Authors of a meta-analysis aimed to systematically assess the safety and efficacy profile of rituximab in patients with systemic sclerosis.

Review of Global Incidence and Prevalence of Systemic Sclerosis

Study authors conducted a systematic review and meta-analysis on the incidence and prevalence of systemic sclerosis.

B-Cell Depletion Therapy May Be Safe, Effective for Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

Researchers assessed the safety and efficacy of B-cell depletion for systemic sclerosis-associated pulmonary arterial hypertension.

Tocilizumab Approved for the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease

The FDA has approved Actemra® (tocilizumab; Genentech) subcutaneous injection for slowing the rate of decline in pulmonary function in SSc-ILD.

Low Back Pain Is a Major Driver of Pain in Very Early Systemic Sclerosis

The researchers conducted an extensive pain assessment of patients with systemic sclerosis, examining pain chronification and its association with disease manifestations.

Esophageal Dysphagia Predicts PPI-Partial Response GERD in Systemic Sclerosis

A team of investigators sought to determine the prevalence of proton pump inhibitor-partial response gastroesophageal reflux disease in patients with systemic sclerosis.

Sitaxsentan Designated Orphan Drug for Systemic Sclerosis

The FDA has granted Orphan Drug designation to TMB-003 (Timber Pharmaceuticals) for the treatment of systemic sclerosis.

Obstetric Complications Common Among Women Who Develop Systemic Sclerosis

Researchers evaluated obstetric complications in women with a systemic sclerosis diagnosis vs the general obstetric population.

Revised CRISS Developed to Improve dcSSc Study Outcome Measures

The performance of 5 core set measure in ACR-CRISS in recent trials was explored, and their ability to discern the active medication group from placebo in patients with diffuse cutaneous systemic sclerosis (dcSSc), was assessed.